Werewolf Therapeutics Inc
HOWL
Market Cap$263.12M
Close$
$4.11
32.4% downside
Current Fair Value
32.4% downsideOvervalued by 32.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $263.12 Million |
|---|---|
| Enterprise Value | $180.70 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-1.05 |
| Beta | 0.0 |
| Outstanding Shares | 43,347,363 |
| Avg 30 Day Volume | 195,260 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -7.04 |
|---|---|
| PEG | -1150.72 |
| Price to Sales | - |
| Price to Book Ratio | 3.04 |
| Enterprise Value to Revenue | 9.06 |
| Enterprise Value to EBIT | -4.46 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.29 |
| Debt to Equity | 0.47 |
Revenue Sources
No data
ESG Score
No data
About Werewolf Therapeutics Inc
28 employeesWerewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its proprietary PRE...